DALLAS--(BUSINESS WIRE)--Vivione Biosciences Inc. (“Vivione” or the “Company”) (TSXV:VBI) today announced the termination of Ted Moskal as President of Vivione and its operating subsidiary, Vivione Biosciences, LLC.
“Ted had a long-standing tenure with Vivione, and we appreciate his contributions,” said Vivione’s Chief Executive Officer, Kevin Kuykendall. “However, as the Company matured and expanded into other markets such as clinical and oil & gas, we began to grow the management team with individuals that were proficient in the areas in which the Company was moving and it became clear that a change needed to be made.”
Day-to-day responsibilities with the FDA will be assumed by our Chief Medical Officer, Dr. Matthew Gombrich.
About Vivione
Formed in 2006 in collaboration with the FDA, Vivione is a TSX Venture Exchange listed biosciences company focused on the commercialization of its proprietary RAPID-B system; an integrated system of hardware, software and chemical reagents that quickly and accurately identify, quantify and qualify bacteria and other pathogens in food safety, bio-therapeutics, clinical, industrial and oil & gas environments. For more information, visit www.VivioneBiosciences.com.
Cautionary Statements
This news release contains "forward-looking statements" within the meaning of applicable securities laws. Although Vivione believes that the expectations reflected in its forward-looking statements are reasonable, such statements have been based on factors and assumptions concerning future events that may prove to be inaccurate. These factors and assumptions are based upon currently available information to Vivione. Such statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. This news release contains forward-looking information relating to the commercialization and the development of the RAPID-B system and Vivione’s business and growth. Readers are cautioned to not place undue reliance on forward-looking statements. The statements in this news release are made as of the date of this news release and, except as required by applicable law, Vivione does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. Vivione undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Vivione, or its financial or operating results or (as applicable), their securities.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
